High-Quality CGT Poseida Therapeutics: Thermo Fisher & Miltenyi Solutions

Poseida Therapeutics is pleased to announce a new collaboration with T&L Biotechnology Co., Ltd. to develop and commercialize a groundbreaking Chimeric Antigen Receptor T-cell (CAR-T) therapy for the treatment of cancer. This joint venture utilizes Poseida's innovative gene editing technology and CGT expertise with T&L's extensive experience in biotechnology and manufacturing, This partnership aims to revolutionize cancer treatment by combining Poseida's cutting-edge CAR-T platform with T&L's advanced manufacturing capabilities. The resulting therapy has the potential to significantly improve patient outcomes and redefine the standard of care for cancer, By leveraging the strengths of both companies, we are committed to advancing the development of this promising therapy and bringing it to patients in need as efficiently as possible. Together, we are dedicated to delivering innovative and effective treatment options that have the potential to transform the lives of cancer patients, We are excited about the possibilities that this collaboration presents and look forward to the positive impact it could have on the field of cancer therapy